Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - Salarius Pharmaceuticals, Inc. | slrx12312019-321exhibi.htm |
| EX-31.2 - EX-31.2 - Salarius Pharmaceuticals, Inc. | slrx12312019-312exhibi.htm |
| EX-31.1 - EX-31.1 - Salarius Pharmaceuticals, Inc. | slrx20191231ex-311.htm |
| EX-23.2 - EX-23.2 - Salarius Pharmaceuticals, Inc. | slrx12312019weavercons.htm |
| EX-23.1 - EX-23.1 - Salarius Pharmaceuticals, Inc. | slrx12312019eyconsent1.htm |
| EX-10.9 - EX-10.9 - Salarius Pharmaceuticals, Inc. | slrx20191231-brucemccr.htm |
| EX-10.7 - EX-10.7 - Salarius Pharmaceuticals, Inc. | slrx20191231seperation.htm |
| EX-4.9 - EX-4.9 - Salarius Pharmaceuticals, Inc. | slrx12312019descriptio.htm |
| 10-K - 10-K - Salarius Pharmaceuticals, Inc. | flks-20191231.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K for the year ended December 31, 2019 of Salarius Pharmaceuticals, Inc. (the “Company”), as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Mark Rosenblum, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
1.the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| Dated: March 23, 2020 | By: | /s/ Mark Rosenblum | ||||||
Name: Mark Rosenblum | ||||||||
| Title: Chief Financial Officer (Principal Financial Officer) | ||||||||